Gene | Type of Use | Billing for clinical use | |||
---|---|---|---|---|---|
Research Use | Clinical Use | Third parties | Patients | Institutional support | |
ABCB1 | 5 | 1 | . | . | 1 |
ABCC2 | 3 | . | . | . | . |
ABCC3 | 2 | . | . | . | . |
ABCC4 | 2 | . | . | . | . |
CYP2B6 | 5 | 2 | 1 | 1 | 3 |
CYP2C cluster rs12777823 | 6 | 3 | 1 | 1 | 3 |
CYP2C19 | 10 | 13 | 10 | 2 | 7 |
CYP2C8 | 4 | . | . | . | 1 |
CYP2C9 | 7 | 8 | 4 | 1 | 6 |
CYP2D6 | 8 | 8 | 4 | 1 | 5 |
CYP3A4 | 7 | 2 | 1 | 1 | 3 |
CYP3A5 | 7 | 5 | 2 | 1 | 4 |
CYP4F2 | 5 | 3 | 2 | 1 | 4 |
DPYD | 5 | 3 | 1 | 1 | 3 |
DRD1 | 2 | . | . | . | . |
DRD2 | 5 | 1 | . | . | 2 |
FAAH | 3 | . | . | . | . |
G6PD | 4 | 1 | 1 | 1 | 1 |
GRIN2A | 2 | . | . | . | . |
HLA A 31 01 | 5 | 3 | . | . | 2 |
HLA B 15 02 | 5 | 3 | . | . | 2 |
HLA B 57 01 | 5 | 4 | 1 | 1 | 2 |
HLA B 58 01 | 5 | 3 | . | . | 2 |
HTR2A | 6 | 1 | 1 | 1 | 3 |
HTR2C | 5 | 1 | 1 | 1 | 3 |
IFNL3 | 4 | 3 | 1 | . | 2 |
ITPA | 3 | 1 | 1 | 1 | 1 |
MTHFR | 4 | 1 | . | . | 1 |
NUDT15 | 5 | 4 | 1 | 1 | 5 |
1-Oct | 3 | . | . | . | . |
OPRM1 | 6 | 1 | . | . | 2 |
SLC6A4 | 6 | 1 | . | . | 2 |
SLCO1B1 | 8 | 7 | 2 | 1 | 6 |
SV2C | 3 | 1 | 1 | 1 | 1 |
TPMT | 5 | 7 | 6 | 1 | 4 |
UGT1A1 | 5 | 4 | 1 | 1 | 3 |
UGT1A9 | 4 | 1 | 1 | 1 | 1 |
UGT2B15 | 4 | 1 | . | . | . |
UGT2B7 | 4 | 1 | . | . | 1 |
VKORC1 | 7 | 6 | 4 | 1 | 6 |
Average per site | 12.93 | 6.93 | 3.2 | 1.47 | 6.13 |
Range | 2-10 | 0-13 | 0-10 | 0-2 | 0-7 |